Olema Pharmaceuticals (OLMA) EPS (Weighted Average and Diluted) (2020 - 2026)
Olema Pharmaceuticals (OLMA) reported EPS (Weighted Average and Diluted) of -$0.52 for Q1 2026, down 44.44% year-over-year from -$0.94 in Q1 2025, and down 1.96% quarter-over-quarter from -$0.51 in Q4 2025.
Olema Pharmaceuticals (OLMA) EPS (Weighted Average and Diluted) (2020 - 2026) Analysis & Trends
Olema Pharmaceuticals (OLMA) has 7 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.52 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.52, down 44.44% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.03 (down 6.84% YoY), and the FY2025 annual result was -$1.87, up 15.0% from the prior year.
- EPS (Weighted Average and Diluted) eased to -$0.52 in Q1 2026 per OLMA's latest filing, from -$0.51 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at -$0.36 in Q1 2025 and troughed at -$0.82 in Q2 2022.
- A 5-year average of -$0.54 and a median of -$0.52 in 2026 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) plunged 95.24% in 2022, then surged 40.24% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.65 in 2022, then increased by 26.15% to -$0.48 in 2023, then climbed by 16.67% to -$0.4 in 2024, then decreased by 27.5% to -$0.51 in 2025, then retreated by 1.96% to -$0.52 in 2026.
- Business Quant data shows OLMA's EPS (Weighted Average and Diluted) at -$0.52 in Q1 2026, -$0.51 in Q4 2025, and -$0.49 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 0.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -0.61 |
| 10 | Olema Pharmaceuticals | 1.08 Bn | 1.08 Bn | - | -0.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.52 |
| Dec 31, 2025 | -0.51 |
| Sep 30, 2025 | -0.49 |
| Jun 30, 2025 | -0.51 |
| Mar 31, 2025 | -0.36 |
| Dec 31, 2024 | -0.40 |
| Sep 30, 2024 | -0.60 |
| Jun 30, 2024 | -0.54 |
| Mar 31, 2024 | -0.56 |
| Dec 31, 2023 | -0.48 |
| Sep 30, 2023 | -0.48 |
| Jun 30, 2023 | -0.49 |
| Mar 31, 2023 | -0.70 |
| Dec 31, 2022 | -0.65 |
| Sep 30, 2022 | -0.57 |
| Jun 30, 2022 | -0.82 |
| Mar 31, 2022 | -0.58 |
| Dec 31, 2021 | -0.55 |
| Sep 30, 2021 | -0.45 |
| Jun 30, 2021 | -0.42 |